ANI Pharmaceuticals announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug Nizoral. U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2M, based on July 2024 moving annual total IQVIA data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James
- ANI Pharmaceuticals completes acquisition of Alimera Sciences
- ANI Pharmaceuticals initiates closing of acquisition of Alimera Sciences
- ANI Pharmaceuticals launches Promethazine Hydrochloride
- Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls